



**PharmTech**

## **International Journal of PharmTech Research**

CODEN (USA): IJPRIF, ISSN: 0974-4304, ISSN(Online): 2455-9563  
Vol.13, No.03, pp 283-287, 2020

### **COVID-19 an Updated Roadmap – Current Scenario and Recent Development**

**J.Yamuna<sup>1\*</sup>, C. Sownthariya<sup>2</sup>, S N Khadatkhar<sup>3</sup>**

<sup>1</sup>Department of Chemistry, Holy Cross College, Tiruchirappalli, India

<sup>2</sup>Department of Botany, Holy Cross College, Tiruchirappalli, India

<sup>3</sup>Geetadevi Khandelwal Institute of Pharmacy, Akola, MS, India

**Abstract :** Coronavirus (COVID-19) is associated with human-to-human transmission. And it causes severe respiratory and systemic infection. Research interest on coronaviruses has been increased after the outbreak of the highly pathogenic Severe Acute respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Wuhan, China was first infected country for COVID-19 and it is now spread worldwide. As on April 14 there are more than 100,000 death reported all over the country. The animal to human transmission is suspected to be the route cause of the viruses. Further investigation need to be confirmed for the origin of the noval virus. COVID-19 was recently identified in saliva of infected people. So the potential transmission of the virus is through saliva of infected people. In this article, we discuss the roadmap of COVID-19 and summerised the clinical clarification, diagnosis, causes and risk factor, currently available test, screening and prevention.

**Keywords :** COVID-19, Human-to human, Symptoms, Chloroquine, Respiratory issues, Mucus.

J.Yamuna *et al* //International Journal of PharmTech Research, 2020,13(3): 283-287.

DOI= <http://dx.doi.org/10.20902/IJPTR.2019.130320>

\*\*\*\*\*